Fundraising FoxOrigin Life Sciences
Princeton, US · Delaware corporation
Find your way into Origin Life Sciences
Sign up to see every warm intro you have to Origin Life Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Origin Life Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Origin Life Sciences is a clinical-stage biotechnology company developing IonoJet, a patented high-energy plasma device that generates and delivers a nitric oxide plasma stream to targeted areas of the body. Its therapy is being developed for chronic wound healing, skin and soft tissue infections, and other indications including dermatology, infection control, podiatry, and dentistry.
Founders & leadership
JF
John FernandesChief Financial OfficerHe has held finance leadership and controller roles across biotechnology, consumer products, insurance, and food manufacturing, with international experience in Europe, Asia, and the Americas.
DD
David DantzkerChief Medical Officer
MD
Michael David PrestonChief Executive Officer
JB
Jerome Boda KortenNamed on SEC filing
AB
Anthony BramptonNamed on SEC filing
VM
Victor MicatiNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 4 rounds · 2017–2023
▶$51KraisedOct 2023 · 2 investors · BiotechnologyRule 506(b)
▶$51KraisedOct 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael David PrestonExecutive Officer, Director
- Jerome Boda KortenDirector
- Victor MicatiDirector
- David DantzkerExecutive Officer, Director
- John FernandesExecutive Officer
- Anthony BramptonDirector
- Offering amount
- $5M
- Amount sold
- $51K
- Minimum investment
- $1K
- Sales commissions
- $3.6K
- Placement agents
- Boustead Securities, LLC
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$659.6KraisedJun 2023 · 6 investors · BiotechnologyRule 506(b)
▶$659.6KraisedJun 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John FernandesExecutive Officer
- Jerome Boda KortenDirector
- David DantzkerExecutive Officer, Director
- Anthony BramptonDirector
- Michael David PrestonExecutive Officer, Director
- Victor MicatiDirector
- Offering amount
- $850K
- Amount sold
- $659.6K
- Minimum investment
- $5K
- Sales commissions
- $46.2K
- Placement agents
- Boustead Securities, LLC
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedSep 2022 · 7 investors · BiotechnologyRule 506(b)
▶$500KraisedSep 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David DantzkerExecutive Officer, Director
- Michael David PrestonExecutive Officer, Director
- Alex Dolgopolsky, PhDExecutive Officer
- Howard NelsonDirector
- Tony BramptonDirector
- Johnny FernandesExecutive Officer
- Vic MicatiDirector
- Mike PohlExecutive Officer
- Offering amount
- $5M
- Amount sold
- $500K
- Sales commissions
- $40K
- Placement agents
- BOUSTEAD SECURITIES, LLC
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMay 2017 · 32 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2017 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tony BramptonDirector
- Michael David PrestonExecutive Officer, Director
- Johnny FernandesExecutive Officer
- Howard NelsonExecutive Officer, Director
- David Dantzker, MDExecutive Officer, Director
- Vic MicatiDirector
- Betsy HannaExecutive Officer
- Offering amount
- $22.5M
- Amount sold
- $1.3M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
OriginOrigin generates spatial molecular maps from patient tumor samples to enable cancer biology research in native tissue context. The platform combines spatial transcriptomics, imaging, and functional perturbation assays on fresh and archived tumors, paired with AI models for drug response prediction and target discovery.
OriginOrigin collaborates with People/HR teams to guide employees through personal financial matters including compensation, benefits, and equity. The company helps reduce employer liability related to employee financial wellness.
OriginOrigin provides pelvic floor physical therapy for women and individuals with vaginal anatomy through in-clinic and virtual care. The company operates 20 clinics across the U.S. and delivers specialized treatment for conditions like postpartum recovery, menopause, and pelvic pain.
OriginOrigin Bank is a regional financial institution serving businesses, municipalities, and personal clients across the southern United States. Operating more than 60 banking centers in Texas, Louisiana, Mississippi, Alabama, and Florida since 1912, it provides a broad range of financial services with an emphasis on relationship banking and personalized service.
Companies working in the same space as Origin Life Sciences.
Frequently asked questions
- What does Origin Life Sciences do?
- Origin Life Sciences is a clinical-stage biotechnology company developing IonoJet, a patented high-energy plasma device that generates and delivers a nitric oxide plasma stream to targeted areas of the body. Its therapy is being developed for chronic wound healing, skin and soft tissue infections, and other indications including dermatology, infection control, podiatry, and dentistry.
- How much funding has Origin Life Sciences raised?
- Origin Life Sciences has disclosed $2.5M raised across 4 rounds.
- Where is Origin Life Sciences headquartered?
- Origin Life Sciences is headquartered in Princeton, US.